Aldeyra Therapeutics (ALDX) to Release Quarterly Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX) is scheduled to issue its quarterly earnings data on Thursday, March 7th.

Aldeyra Therapeutics Stock Down 0.3 %

Aldeyra Therapeutics stock traded down $0.01 during mid-day trading on Wednesday, reaching $3.92. The stock had a trading volume of 249,582 shares, compared to its average volume of 496,255. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.81 and a current ratio of 6.81. Aldeyra Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $11.97. The stock’s 50-day simple moving average is $3.38 and its 200-day simple moving average is $4.00. The firm has a market capitalization of $230.57 million, a PE ratio of -5.17 and a beta of 1.53.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Aldeyra Therapeutics by 23.2% in the fourth quarter. Vanguard Group Inc. now owns 3,927,597 shares of the biotechnology company’s stock worth $13,786,000 after acquiring an additional 740,177 shares during the period. BlackRock Inc. boosted its stake in shares of Aldeyra Therapeutics by 228.0% during the 2nd quarter. BlackRock Inc. now owns 3,230,414 shares of the biotechnology company’s stock valued at $27,103,000 after purchasing an additional 2,245,432 shares in the last quarter. State Street Corp raised its stake in Aldeyra Therapeutics by 1,655.5% in the second quarter. State Street Corp now owns 3,041,866 shares of the biotechnology company’s stock worth $25,521,000 after buying an additional 2,868,585 shares in the last quarter. Knoll Capital Management LLC lifted its holdings in Aldeyra Therapeutics by 45.9% in the second quarter. Knoll Capital Management LLC now owns 3,015,668 shares of the biotechnology company’s stock worth $25,301,000 after buying an additional 948,508 shares during the period. Finally, Verition Fund Management LLC grew its holdings in shares of Aldeyra Therapeutics by 54.1% during the 1st quarter. Verition Fund Management LLC now owns 2,105,907 shares of the biotechnology company’s stock worth $9,361,000 after acquiring an additional 739,206 shares during the period. 66.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 29th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.